首页> 外文期刊>Korean Circulation Journal >The Rescue Use of A Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab; Reo-Pro ) in High-Risk Patients with Acute Myocardial Infarction Underwent Percutaneous Coronary Intervention
【24h】

The Rescue Use of A Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab; Reo-Pro ) in High-Risk Patients with Acute Myocardial Infarction Underwent Percutaneous Coronary Intervention

机译:血小板糖蛋白IIb / IIIa受体阻滞剂(Abciximab; Reo-Pro)在高危急性心肌梗死患者中的经皮冠状动脉介入治疗

获取原文
获取外文期刊封面目录资料

摘要

Background Platelets are known to play a major role in the ischemic complications of percutaneous coronary intervention (PCI). Accordingly, we evaluated the effect of rescue use of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab; Reo-Pro ) in Korean patients with acute myocardial infarction (AMI) at high risk for the ischemic complications who underwent PCI. Method Sixty eight patients (54 male, 59.1±9.96 years) treated by the rescue use of Reo-Pro out of 1,117 patients underwent PCI at Chonnam National University Hospital from Mar 1999 to Feb 2000. All of target lesions were thrombus-containing lesions in patients with AMI. The primary end points consisted of any of the followings : cardiac death, nonfatal MI, repeated revascularization. The number of end-point events were tabulated at 6 months after PCI. Results The primary success rate was 92.6% (63/68). At primary end points, there were 5 cases (7.3%), composed of 2 deaths (2.9%), 1 MI, 2 repeated revascularization (2.9%). There was no major bleeding complication after PCI. At secondary end point, there were 23 cases (34.9%) including primary end point, composed of 3 deaths (4.4%), 1 MI and 19 revascularization (28.0%). Conclusion The rescue Reo-Pro can be used safely and effectively in high-risk Korean patients with AMI.
机译:背景技术已知血小板在经皮冠状动脉介入治疗(PCI)的缺血性并发症中起主要作用。因此,我们评估了血小板糖蛋白IIb / IIIa受体阻滞剂(Abciximab; Reo-Pro)的抢救性使用对接受PCI缺血性并发症高风险的韩国急性心肌梗死(AMI)患者的作用。方法1999年3月至2000年2月,在全南国立大学医院行PCI的1117例患者中,有68例患者(54例男性,59.1±9.96岁)接受了Reo-Pro的急诊治疗。 AMI患者。主要终点包括以下任何一项:心源性死亡,非致命性心肌梗死,反复血运重建。在PCI后6个月将端点事件的数量制成表格。结果初步成功率为92.6%(63/68)。在主要终点,有5例(7.3%),包括2例死亡(2.9%),1例MI,2例再次血运重建(2.9%)。 PCI后无大出血并发症。在次要终点,包括主要终点在内的23例(34.9%),包括3例死亡(4.4%),1例MI和19例血运重建(28.0%)。结论抢救性Reo-Pro可以安全有效地用于韩国高危AMI患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号